Stocks · News reference

INmune Bio To Present New Imaging Data From Phase 2 Study Of XPro In Patients With Early Alzheimer’s Disease At AAIC

Jul 9, 2026, 11:03 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 26, 2026, 11:15 AMBenzinga Newsdesk
INmune Bio Submits Two Regulatory Packages To EMA For Ebstrocel: Application For Orphan Drug Designation And Scientific Advice Package To Streamline Upcoming MAA In Europe
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may
INMB
BenzingaAug 6, 2026, 8:01 PMBenzinga Newsdesk
INmune Bio Q2 EPS $(0.05) Beats $(0.21) Estimate
INMB
SEC EDGARJul 31, 2026, 8:06 PMSEC EDGAR
8-K filing — Inmune Bio, Inc. (INMB)
Filed: 2026-07-31 AccNo: 0001213900-26-083961 Size: 231 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
INMB
BenzingaJul 20, 2026, 11:17 AMBenzinga Newsdesk
INmune Bio Reaches Manufacturing Milestone with First Commercial-Ready CORDStrom Umbilical Cord Tissue Processed At CGT Catapult In Partnership With Anthony Nolan Cord Blood Bank
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.Company Expresses Support for MHRA Draft Rare Disease Therapies
INMB